Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
暂无分享,去创建一个
R. Plummer | A. Italiano | L. Dirix | J. Spicer | H. Verheul | C. Rolfo | G. Jerusalem | S. Rottey | K. Leunen | E. Dean | S. Spencer | C. Goessl | L. R. Molife | J. Birkett | J. Greve | M. Learoyd | Christopher J Bailey | F. D. Vos | Peter Grundtvig-Sørensen | J. Grève | F. Vos
[1] Val Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[2] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.
[3] D. Matei,et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. , 2016, The Lancet. Oncology.
[4] R. Plummer,et al. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. , 2016, Clinical Therapeutics.
[5] H. Kaplan,et al. Therapy-related myelodysplastic syndrome following primary breast cancer. , 2016, Leukemia research.
[6] R. Plummer,et al. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib , 2016, Targeted Oncology.
[7] R. Plummer,et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours , 2015, Cancer Chemotherapy and Pharmacology.
[8] Karen So,et al. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors , 2015, Advances in Therapy.
[9] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[11] Zeruesenay Desta,et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. , 2010, British journal of clinical pharmacology.
[12] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[13] P. Borst,et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.
[14] A. Lau,et al. Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.
[15] D. Buckley,et al. Role of Human Pregnane X Receptor in Tamoxifen- and 4-Hydroxytamoxifen-Mediated CYP3A4 Induction in Primary Human Hepatocytes and LS174T Cells , 2008, Drug Metabolism and Disposition.
[16] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[17] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[18] A. Tutt,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.
[19] A. Tutt,et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.